Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | TSHR | P16473 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | ALB | P02768 | 1/20 | 0.76 |
| ▸ | FBP1 | P09467 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbutamide SCHEMBL4078762 | 1.00 | ALDH1A1 (0.76) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Carbutamide SCHEMBL7615910 | 0.91 | ALDH1A1 (0.78) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Tolbutamide SCHEMBL15918 | 0.87 | ALDH1A1 (1.00) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Tolbutamide SCHEMBL1536920 | 0.87 | ALDH1A1 (1.00) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| SCHEMBL11390868 | 0.86 | CYP2C9 (0.69) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Carbutamide SCHEMBL7833740 | 0.86 | CYP2C9 (0.61) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Tolbutamide SCHEMBL7551276 | 0.85 | ALDH1A1 (0.97) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Tolbutamide SCHEMBL11357518 | 0.85 | ALDH1A1 (0.97) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Tolbutamide SCHEMBL140363 | 0.85 | ALDH1A1 (0.97) | ALDH1A1TSHRCYP2C9LMNATDP1 | |
| Tolbutamide SCHEMBL4367531 | 0.85 | ALDH1A1 (0.97) | ALDH1A1TSHRCYP2C9LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4937 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| EP-4520343-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-03-12 | — | — | EP | claimed |
| EP-3988123-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-26 | — | — | EP | claimed |
| US-12208071-B2 | Glucagon receptor antagonists | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-01-28 | — | — | US | claimed |
| US-12186329-B2 | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-07 | — | — | US | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| US-20240366579-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-11-07 | — | — | US | claimed |
| CN-118555971-A | Amorphous photosensitive particles, methods of making and methods of using the same | 马里兰大学帕克分校 | 2024-08-27 | — | — | CN | claimed |
| EP-4329756-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2024-03-06 | — | — | EP | claimed |
| US-20240065979-A1 | Protection of Polyunsaturated Fatty Acids, Lipid-Soluble Vitamins, and Lipid-Soluble Medicaments from Oxidation | One Idea LLC (US) | 2024-02-29 | — | — | US | claimed |
| EP-1001784-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOSIDASE INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2000-05-24 | — | — | EP | claimed |
| WO-2000027434-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTIDIABETIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | claimed |
| EP-0998291-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA | SMITHKLINE BEECHAM PLC (GB) | 2000-05-10 | — | — | EP | claimed |
| WO-1999003478-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1999003477-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1999003476-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA | SMITHKLINE BEECHAM PLC (GB) | 1999-01-28 | — | — | WO | claimed |
| US-5719192-A | ORALLY ADMINISTERING TO TREAT PNEUMOCYSTIS CARINII PNEUMONIA | MENDES S.R.L. (IT) | 1998-02-17 | — | — | US | claimed |
| EP-0692963-A1 | USE OF TERBINAFINE FOR THE THERAPEUTIC TREATMENT OF PNEUMOCYSTOSIS | Mendes S.R.L. (IT) | 1996-01-24 | — | — | EP | claimed |
| WO-1994020082-A1 | USE OF TERBINAFINE FOR THE THERAPEUTIC TREATMENT OF PNEUMOCYSTOSIS | MENDES S.R.L. (IT) | 1994-09-15 | — | — | WO | claimed |
| US-4116949-A | WATER-SOLUBLE, PHYSIOLOGICALLY ACTIVE, SYNTHETIC COPOLYPEPTIDES | THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1978-09-26 | — | — | US | claimed |